Follow
Josep M Llibre
Josep M Llibre
Senior Consultant, University Hospital Germans Trias, Barcelona. Spain
Verified email at lluita.org
Title
Cited by
Cited by
Year
Initiation of antiretroviral therapy in early asymptomatic HIV infection.
JD Lundgren, AG Babiker, F Gordin, S Emery, B Grund, S Sharma, ...
The New England journal of medicine 373 (9), 795-807, 2015
21362015
Initiation of antiretroviral therapy in early asymptomatic HIV infection
Insight Start Study Group
New England Journal of Medicine 373 (9), 795-807, 2015
11302015
HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects
M J Buzón, M Massanella, JM Llibre, A Esteve, V Dahl, MC Puertas, ...
Nature medicine 16 (4), 460-465, 2010
6502010
Dolutegravir in antiretroviral-experienced patients with raltegravir-and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study
A Castagna, F Maggiolo, G Penco, D Wright, A Mills, R Grossberg, ...
The Journal of infectious diseases 210 (3), 354-362, 2014
4152014
Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 …
JM Llibre, CC Hung, C Brinson, F Castelli, PM Girard, LP Kahl, EA Blair, ...
The Lancet 391 (10123), 839-849, 2018
3952018
Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection
E Martínez, JA Arnaiz, D Podzamczer, D Dalmau, E Ribera, P Domingo, ...
New England Journal of Medicine 349 (11), 1036-1046, 2003
3872003
Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study
E Martinez, M Larrousse, JM Llibre, F Gutierrez, M Saumoy, A Antela, ...
Aids 24 (11), 1697-1707, 2010
2402010
Characteristics, comorbidities, and outcomes in a multicenter registry of patients with human immunodeficiency virus and coronavirus disease 2019
D Dandachi, G Geiger, MW Montgomery, S Karmen-Tuohy, M Golzy, ...
Clinical Infectious Diseases 73 (7), e1964-e1972, 2021
2102021
A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study)
D Podzamczer, E Ferrer, E Consiglio, JM Gatell, P Perez, JL Perez, ...
Antiviral therapy 7 (2), 81-90, 2002
1962002
Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study
D Podzamczer, E Ferrer, P Sanchez, JM Gatell, M Crespo, C Fisac, ...
JAIDS Journal of Acquired Immune Deficiency Syndromes 44 (2), 139-147, 2007
1812007
Sexual transmission of hepatitis C virus and its relation with hepatitis B virus and HIV.
J Tor, JM Llibre, M Carbonell, R Muga, A Ribera, V Soriano, B Clotet, ...
British Medical Journal 301 (6761), 1130-1133, 1990
1701990
Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week study
JM Llibre, MJ Buzón, M Massanella, A Esteve, V Dahl, MC Puertas, ...
Antiviral therapy 17 (2), 355-364, 2012
1422012
Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir
E Martínez, MD Polyana, JM Llibre, F Gutierrez, D Podzamczer, A Antela, ...
Aids 26 (18), 2315-2326, 2012
1342012
Genetic barrier to resistance for dolutegravir.
JM Llibre, F Pulido, F García, M Garcia Deltoro, JL Blanco, R Delgado
AIDS reviews 17 (1), 2015
1302015
Lymphogranuloma venereum proctocolitis: a silent endemic disease in men who have sex with men in industrialised countries
R Martin-Iguacel, JM Llibre, H Nielsen, E Heras, L Matas, R Lugo, B Clotet, ...
European journal of clinical microbiology & infectious diseases 29, 917-925, 2010
1272010
The lipid-lowering effect of tenofovir/emtricitabine: a randomized, crossover, double-blind, placebo-controlled trial
JR Santos, M Saumoy, A Curran, I Bravo, JM Llibre, J Navarro, C Estany, ...
Clinical Infectious Diseases 61 (3), 403-408, 2015
1202015
Efficacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virological suppression receiving a LPV/r-containing HAART: the ATAZIP study
J Mallolas, D Podzamczer, A Milinkovic, P Domingo, B Clotet, E Ribera, ...
JAIDS Journal of Acquired Immune Deficiency Syndromes 51 (1), 29-36, 2009
1192009
A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1-infected …
E Martínez, JA Arranz, D Podzamczer, M Loncá, J Sanz, P Barragán, ...
JAIDS Journal of Acquired Immune Deficiency Syndromes 51 (3), 290-297, 2009
1122009
Sustained improvement of dyslipidaemia in HAART-treated patients replacing stavudine with tenofovir
JM Llibre, P Domingo, R Palacios, J Santos, MJ Pérez-Elías, ...
Aids 20 (10), 1407-1414, 2006
1082006
Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patients
L Ruiz, R Paredes, G Gómez, J Romeu, P Domingo, N Pérez-Alvarez, ...
Aids 21 (2), 169-178, 2007
1072007
The system can't perform the operation now. Try again later.
Articles 1–20